Format

Send to

Choose Destination
Transpl Infect Dis. 2010 Dec;12(6):513-7. doi: 10.1111/j.1399-3062.2010.00582.x. Epub 2010 Nov 10.

Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.

Author information

1
Département de Microbiologie et Immunologie, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada.

Abstract

Oseltamivir resistance in pandemic 2009 influenza A/H1N1 is caused by the neuraminidase mutation H275Y. This mutation has also been associated with in vitro resistance to peramivir, but few clinical cases have been described to date. Using allele-specific real-time reverse transcriptase polymerase chain reaction assay for the H275Y mutation, we were able to identify resistant H1N1 in a hematopoietic cell transplant recipient receiving intravenous peramivir therapy, and through serial testing we determined the molecular evolution of resistance. This case demonstrates that an H275Y mutant population can emerge early and replicate in vivo under peramivir antiviral pressure to become the major viral population.

PMID:
21062390
PMCID:
PMC3024056
DOI:
10.1111/j.1399-3062.2010.00582.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center